Nabriva Therapeutics — Investor Presentation (April 2016)
31 slides from Nabriva Therapeutics's investor presentation, Apr 12, 2016
Slide 1: Safe Harbor
Safe Harbor This presentation contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this presentation, including statements regarding our strategy, future operations, future financial position, fu
Slide 2: Nabriva Corporate Strategy
Nabriva Corporate Strategy Become a Fully Integrated Company Focused on Novel Antibiotics for Serious Infections Complete Phase 3 trials and obtain regulatory approval of lefamulin for Community Acquired Bacterial Pneumonia (CABP) Maximize the commercial potential of lefamulin for CABP Pursue the de
Slide 3: Nabriva Summary
Nabriva Summary Developing novel antibiotics for serious infections Pleuromutilins – new class of antibiotics for systemic human use in phase 3 development Novel mechanism of action with potent in vitro activity against multi-drug resistant (MDR) strains Proprietary platform and IP wholly owned by N
Slide 4: Nabriva Expertise in Pleuromutilin Research and Development
Nabriva Expertise in Pleuromutilin Research and Development 5 1999 Sandoz Antibiotics Research Institute Vienna (ABRI) 2006 NABRIVA Spin-off from Sandoz Pleuromutilin SAR knowledge and small molecule assets transferred to Nabriva 2015 NABRIVA Pleuromutilins in development synthesized by Nabriva Sept
Slide 5: Developing Semi-Synthetic Pleuromutilins to Combat Bacterial Resistance
Developing Semi-Synthetic Pleuromutilins to Combat Bacterial Resistance Novel mechanism of action Inhibit protein synthesis by binding at the ribosomal peptidyl transferase center (PTC) Lack of cross-resistance observed with other antibiotic classes Potential for slower development of bacterial resi
Slide 6: Nabriva's Pleuromutilin Pipeline is Advancing
Nabriva’s Pleuromutilin Pipeline is Advancing Program Indications Discovery Pre-clinical Phase 1 Phase 2 Phase 3 Comments Lefamulin (IV/oral) CABP* IV/Oral Phase 3 initiated; Oral Phase 3 initiated April 2016 ABSSSI Phase 2 complete Lefamulin (IV/oral) Pediatric Indications Preclinical work and form
Slide 7: Growing Need for New Antibiotics and Novel Mechanisms
Growing Need for New Antibiotics and Novel Mechanisms Supported by Government and Regulatory Agencies 8 Pleuromutilin antibiotics can potentially help address the major public health threat posed by bacterial resistance, which the World Health Organization characterized in 2010 as one of the three g
Slide 8: Lefamulin: First Pleuromutilin Antibiotic for Systemic Therapy in Humans
Lefamulin First Pleuromutilin Antibiotic for Systemic Therapy in Humans
Slide 9: Lefamulin Targeted Positioning as Empiric Monotherapy for CABP
Lefamulin Targeted Positioning as Empiric Monotherapy for CABP Spectrum of activity covering key CABP pathogens, including resistant strains Gram-positive, Gram-negative, atypicals, including multi-drug resistant (MDR) strains Potential for slower development of bacterial resistance Demonstration of
Slide 10: Lefamulin Lead Molecule with Spectrum of Activity Well Suited for CABP
Lefamulin Lead Molecule with Spectrum of Activity Well Suited for CABP Potent activity against key respiratory pathogens including S. aureus Lefamulin has been thoroughly investigated in vitro in vitro activity not affected by increasing antibiotic resistance observed in CABP pathogens: Cephalospori
Slide 11: Lefamulin Therapeutic Effect Observed in Phase 2 Study of ABSSSI
Lefamulin Therapeutic Effect Observed in Phase 2 Study of ABSSSI Lefamulin 100 mg or 150 mg IV q12h vs. vancomycin in 207 patients with ABSSSI Lefamulin achieved clinical response rates comparable to vancomycin Lefamulin was well tolerated Most commonly reported adverse events included headache, nau
Slide 12: Lefamulin Data Supports Advancing to Phase 3 for CABP
Lefamulin Data Supports Advancing to Phase 3 for CABP Lefamulin was efficacious in murine lung and thigh infection models predictive of efficacy in ABSSSI and bacterial respiratory tract infections Greater efficacy against S. aureus and S. pneumoniae in murine lung infection models compared to thigh
Slide 13: Lefamulin Clinical Database Supports Advancing to Phase 3 for CABP
Lefamulin Clinical Database Supports Advancing to Phase 3 for CABP Studied by IV and oral route in more than 400 patients and healthy patients Generally well tolerated by IV and oral routes Transient, Cmax related QTc effect comparable to, or less than, that of moxifloxacin Rapid oral absorption (60
Slide 14: Clinical Development Plan for Differentiation in CABP
Clinical Development Plan for Differentiation in CABP Phase 3 CABP registration program initiated in the fall of 2015 Lefamulin Evaluation of Adults with Pneumonia (LEAP 1) trial (IV to oral) in moderate-to-severe CABP (Pneumonia Outcomes Research Team (PORT) III, IV and V) Site selection planned to
Slide 15: LEAP 1 and 2 Phase 3 Trial Designs for the Treatment of CABP
LEAP Phase 3 Trial Designs for the Treatment of CABP Double-blind, randomized, active comparator >100 multinational centers Stratification according to: Geographic region (US vs. ex-US) Prior short-acting antibiotic therapy for CABP vs. none No more than 25% of randomized patients will have prior sh
Slide 16: LEAP 1 and 2: Powering and Primary Objectives
LEAP 1 and 2: Powering and Primary Objectives 90% power to establish the non-inferiority (NI) of lefamulin to moxifloxacin for both FDA and EMA endpoints using a NI margin of 10% FDA Endpoint: NI of lefamulin vs. comparator with respect to Early Clinical Response 96 ± 24 hours after first dose of st
Slide 17: LEAP 1 and 2: Treatment Scenarios
LEAP 1 and 2: Treatment Scenarios LEAP 1 All patients: IV therapy for a minimum of three days before switching to oral therapy Majority of patients will receive 5 days of lefamulin vs. 7 days moxifloxacin Patients receive 10 days if: S. pneumoniae with bacteremia L. pneumophila MRSA suspected at bas
Slide 18: LEAP 1 and 2: Treatment Scenarios
LEAP 1 and 2: Treatment Scenarios LEAP 1 = All patients: IV therapy for a minimum of three days before switching to oral therapy = Majority of patients will receive 5 days of lefamulin vs. 7 days moxifloxacin = Patients receive 10 days if: + S. pneumoniae with bacteremia + L. pneumophila + MRSA susp
Slide 19: Present and Emerging Issues in the Treatment of CABP
Present and Emerging Issues in the Treatment of CABP WHOa 2002 estimates: 450 million pneumonia cases reported annually worldwide, resulting in an estimated 4.0 million deaths Approximately 5.6 million cases of pneumonia per year in the US between 1988 and 1994 2014: >1 million in-patient hospitaliz
Slide 20: Most Hospitalized CABP is Treated Empirically with Broad Spectrum Antibiotics
In 2009, Medicare data indicated that an etiologic diagnosis of probable pathogens was established in less than 10% of Medicare patients hospitalized with CABP1 Some research suggests empiric therapy of severe CAP during periods of high influenza activity should include coverage for MRSA, including
Slide 21: IDSA/ATS Treatment Guidelines Recommend Broad Spectrum Empiric Drug Selection
IDSA/ATS Treatment Guidelines Recommend Broad Spectrum Empiric Drug Selection for Hospitalized CABP Patients Non – ICU Inpatient B-lactam (IV or IM) + Macrolide (IV or PO) Respiratory Quinolone (IV or PO) B-lactam (IV or IM) + Doxycycline (IV or PO) B-lactam = Ceftriaxone, Cefotaxime, Ampicillin/Sul
Slide 22: Classes of IV Drugs Represent >80% of US Hospitalized Adult CABP Courses
4 Classes of IV Drugs Represent >80% of Estimated ~5.1M Courses for US Hospitalized Adult CABP Patients in 2014 23 Source: AMR Courses of Therapy, 2014 cephalosporin , 31% fluoroquinolone , 23% macrolide , 17% glycopeptide , 10% penicillin/combo , 10% oxazolidinones , 1% other (tetracycline, carbape
Slide 23: Classes of Oral Drugs Represent >80% of Hospitalized Adult CABP Courses
Only 3 Classes of Oral Drugs Represent >80% of the Estimated ~1.4M Courses for Hospitalized Adult CABP Patients 24 Source: AMR Courses of Therapy, 2014 macrolide , 43% fluoroquinolone , 36% cephalosporin , 7% penicillin combo , 5% tetracycline , 4% other (oxazolidinone, penicillin, etc) , 5% US 2014
Slide 24: Lefamulin Competitive Profile in CABP Compared with Approved Classes
Lefamulin Competitive Profile in CABP Compared with Approved Classes Lefamulin Fluoro-quinolones Macrolides Cephalo-sporins PCN/ BLI Tetra-cyclines Oxazo-lidinones First-in class IV to oral switch Activity vs. MRSA Activity vs. atypicals Activity vs. H. influenzae Targeted Spectrum Empiric monothera
Slide 25: IP, Financing History and Milestones
IP, Financing History and Milestones
Slide 26: Nabriva Has a Strong and Broad Patent Portfolio
Nabriva Has a Strong and Broad Patent Portfolio 27 Nabriva currently has 19 worldwide pleuromutilin patent families active on file Most of the global pleuromutilin IP landscape is covered (including US, Europe, Japan) Lefamulin IP protected at least until 2028 by several layers Composition of matter
Slide 27: Initial Public Offering of American Depositary Shares Completed in September 2015
Initial Public Offering of American Depositary Shares (ADSs) Completed in the U.S. in September 2015 10,350,000 ADSs in September 2015 at an offering price of $10.25 per ADS Each ADS represents one tenth (1/10) of a common share Immediately prior to the offering, 1,081,121 common shares outstanding
Slide 28: 2015 Financial Highlights
2015 Financial Highlights Raised cash proceeds of $45.6 million (€42.1 million) from our April 2015 financing Cash and cash equivalents of $125.5 million (€112.0 million) at September 30, 2015 compared to $2.2 million (€1.8 million) at December 31, 2014 Net loss for the nine months ended September 3
Slide 29: Anticipated Key Milestones
Anticipated Key Milestones Initiate second Phase 3 trial (LEAP 2) for CABP 4Q 2016: Interim analysis for LEAP 1 2H 2017: Top-line data from both Phase 3 trials for CABP 2018: Regulatory filings in US and EU (priority review request to FDA) for CABP 30
Slide 30: Nabriva Summary
Nabriva Summary Developing novel antibiotics for serious infections Pleuromutilins – new class of antibiotics for systemic human use in phase 3 development Novel mechanism of action with potent in vitro activity against multi-drug resistant (MDR) strains Proprietary platform and IP wholly owned by N
Slide 31: Nabriva Summary
Nabriva Summary = Developing novel antibiotics for serious infections = Pleuromutilins — new class of antibiotics for systemic human use in phase 3 development + Novel mechanism of action with potent in vitro activity against multi-drug resistant (MDR) strains + Proprietary platform and IP wholly ow
Nabriva Therapeutics — Investor Presentation (April 2016) on 6ix